Search the Newsreel

Is Iovance Biotherapeutics (IOVA) Undervalued As Q2 Earnings Reaffirm Revenue Guidance?

Swedish Orphan Biovitrum (OM:SOBI) Following Its Lacutamab Deal And The Undervalued Narrative

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Swedish Orphan Biovitrum Stock Is Back In Focus Swedish Orphan Biovitrum (OM:SOBI) has drawn fresh attention after a new partnership with Innate Pharma …

Swedish Orphan Biovitrum (OM:SOBI) Stock Looks Strong On Returns But Fully Priced On Earnings

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Swedish Orphan Biovitrum has delivered a strong share price run over the past five years, yet its current valuation checks lean expensive rather …

Iovance Biotherapeutics stock hits 52-week high at 6.94 USD

Iovance Biotherapeutics (IOVA) stock reached a 52-week high of $6.94, marking a 167% increase over the past year and reflecting significant market optimism. The company reported strong Q2 2026 earnings, surpassing Wall Street expectations with revenue of $99.31 million and a narrower-than-anticipated adjusted loss, …

Ion Video Ltd (ASX:IOV): When Will It Breakeven?

Iovance (IOVA) Q2 2026 Earnings Call Transcript

Iovance Biotherapeutics reported record Q2 2026 revenue of $99.3 million, a 66% year-over-year increase, driven by strong Amtagvi demand and achieving a 56% gross margin. The company is expanding its TIL therapy platform into broader solid tumor indications like non-small cell lung cancer and …

Bioventus (BVS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Rob ClaypooleSenior Vice President and Chief Financial Officer - Mark SingletonInvestor Relations - Dave Crawford TAKEAWAYS Revenue -- $153.2 million, an increase …

IOVA Stock Price Prediction 2025-2026 | Iovance Biotherapeutics Inc Forecast

Iovance Biotherapeutics (IOVA) Stock Looks Fairly Valued Despite 222% Returns

Iovance Biotherapeutics (IOVA) stock has seen a significant 221.8% return over the past year, but its current valuation suggests it is now fairly priced rather than cheap. The company scores a mixed 4 out of 6 on Simply Wall St's valuation checks, with a …

Iovance Biotherapeutics (IOVA) Is Up 48.3% After Narrowing Losses And Reaffirming 2026 Revenue Guidance

Is Iovance Biotherapeutics (IOVA) Undervalued On Q2 Earnings And Reaffirmed Guidance?

Iovance Biotherapeutics (IOVA) is gaining investor attention after reporting improved Q2 2026 results, including higher revenue and a narrower net loss, while reaffirming full-year revenue guidance of US$350-370 million. Despite a recent share price surge and a narrative suggesting it's undervalued at $18 compared …

Hennion & Walsh Asset Management Inc. Grows Stock Position in Iovance Biotherapeutics, Inc. $IOVA

Hennion & Walsh Asset Management Inc. significantly increased its stake in Iovance Biotherapeutics (NASDAQ:IOVA) by 100% in the second quarter, now holding 818,913 shares valued at $3.4 million. This move comes as Iovance Biotherapeutics reported strong quarterly revenue growth of 65.7% year-over-year, beating analyst …

Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?

Iovance Biotherapeutics (NASDAQ: IOVA) recently reported strong Q2 earnings, with revenue increasing by 66% due to high demand for its cancer treatment, Amtagvi. The company also significantly reduced its net losses, leading to a surge in stock value and a new 52-week high. Despite …

Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings

The Bull Case For Bioventus (BVS) Could Change Following Its Q2 Earnings Surge And Reaffirmed 2026 Guidance

What is HC Wainwright's Forecast for IOVA Q3 Earnings?

Earnings Beat: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Iovance Biotherapeutics, Inc. recently reported its latest quarterly results, surpassing analyst revenue and earnings estimates. This positive performance has led analysts to revise their forecasts upwards, suggesting increased optimism about the company's future earnings potential. The market reacted positively, with the stock price climbing …

Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of "Buy" from Brokerages

Bioventus (BVS) Is Up 6.1% After Reaffirming 2026 Sales Outlook And Strong Q2 Earnings Jump

Bioventus Inc. (BVS) reported strong Q2 2026 results with a significant jump in net income and reaffirmed its full-year 2026 sales guidance of US$600 million to US$610 million. The company's investment narrative focuses on converting modest sales growth into higher profitability while managing debt. …

Iovance Biotherapeutics (NASDAQ:IOVA) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Form 8K Iovance Biotherapeutics Inc For: 6 August By Investing.com

This article reports on the filing of a Form 8K by Iovance Biotherapeutics Inc. The filing date is stated as August 6th. The article, published by Investing.com, provides no further details beyond the announcement of the 8K filing.

Iovance Biotherapeutics (IOVA) Stock Price Trails Record Revenue And Margin Gains

Iovance Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $8.67, Implies 100% Upside

Iovance Biotherapeutics, Inc. (IOVA) has seen its average 12-month stock price target raised to $8.67 from $8.22 by 9 analysts, implying a potential upside of approximately 100% from its Aug. 5 closing price. The consensus rating for the stock remains "Buy," with 7 analysts …

Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 28.02% as Wall Street Analysts Expect?

Iovance Biotherapeutics (IOVA) closed at $6.21, with Wall Street analysts setting a mean price target of $7.95, suggesting a 28% upside. While an impressive consensus price target is noted, the article cautions against relying solely on these targets due to potential analyst optimism and …

IOVA Q2 Earnings Beat, Stock Jumps 43% on Strong Amtagvi Uptake

IOVANCE BIOTHERAPEUTICS, INC. 2Q 2026: Revenue $99.3M, EPS $(0.11) — 10-Q Summary

IOVANCE BIOTHERAPEUTICS, INC. reported its second-quarter 2026 results, showing significant improvement with revenue of $99.3M and a narrowed net loss of $47.3M. The company's diluted EPS improved to $(0.11), driven by commercial growth, including increased Amtagvi® infusions and higher Proleukin® sales. IOVANCE has also …

Iovance Biotherapeutics (IOVA) Pops 43% on Stellar Q2. Here’s What Comes Next

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) rocketed to a fresh 52-week high on Thursday, clocking as much as 47 percent gains, after management reported a 66 percent jump in revenues that signaled the strengthening demand for its treatment for advanced melanoma. In intra-day trading, the stock …

Iovance plans full-year 2026 revenue guidance update in Q3 while maintaining $1B+ U.S. peak sales assumptions

Earnings Call Insights: Iovance Biotherapeutics (IOVA) Q2 2026 MANAGEMENT VIEW * "The second quarter of 2026 was our strongest yet." (Interim CEO, President, General Counsel, Corporate Secretary & Director Frederick Vogt) "We reported $99.3 million in revenue driven by record Amtagvi demand." "Second quarter …

Bioventus (BVS) Stock Jumps On Profit Strength As Growth Risks Remain

Bioventus (BVS) stock surged 13.7% following a strong Q2 earnings report, showcasing adjusted EBITDA of US$35 million on US$153.2 million revenue and healthy cash generation. While the company's profitability and cash flow are positive, concerns remain regarding its reliance on a narrow product set, …

Why Investors Are Watching These Healthcare Movers

DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- (https://247mnn.com/) – ClearOne (NASDAQ: CLRO), NeOnc Technologies (NASDAQ: NTHI), Iovance Biotherapeutics (NASDAQ:IOVA), and Ensysce Biosciences (NASDAQ:ENSC) are covered in today’s roundup. ClearOne Advances Toward Neurotechnology Transformation ClearOne (NASDAQ:CLRO) continues moving closer to completing its planned transformation into …

Earnings call transcript: Iovance beats Q2 2026 estimates, shares jump 30%

Iovance Biotherapeutics (NASDAQ: IOVA) reported stronger-than-expected Q2 2026 results, with adjusted loss per share narrower than anticipated and revenue exceeding forecasts, driven by robust sales of its cancer therapy Amtagvi. Shares jumped over 30% in premarket trading. The company also announced improved gross margins, …

Iovance shares surge 39% as Amtagvi Q2 revenue and margins surpass expectations

Iovance Biotherapeutics Reports Record Q2 Revenue and Reviews 2026 Outlook on Strong Amtagvi Demand